Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab (Q34627748)

3 August 2017

1 reference

title

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab (English)

1 reference

3 August 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21419116

27 November 2024

2

Patrick A Baeuerle

1 reference

3 August 2017

Dirk Nagorsen

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

16 March 2011

1 reference

full work available at URL

3 August 2017

https://api.elsevier.com/content/article/PII:S0014482711001029?httpAccept=text/xml

1 reference

10.1016/J.YEXCR.2011.03.010

DOI

https://api.crossref.org/works/10.1016/J.YEXCR.2011.03.010

https://api.elsevier.com/content/article/PII:S0014482711001029?httpAccept=text/plain

27 November 2024

1 reference

10.1016/J.YEXCR.2011.03.010

DOI

https://api.crossref.org/works/10.1016/J.YEXCR.2011.03.010

Experimental Cell Research

27 November 2024

published in

1 reference

3 August 2017

volume

317

1 reference

3 August 2017

issue

9

1 reference

3 August 2017

page(s)

1255-1260

1 reference

Immune surveillance of tumors

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Cancer immunotherapy: a treatment for the masses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Use of tumour-responsive T cells as cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Tumor microenvironment and immune escape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Immunosuppressive strategies that are mediated by tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Quantitative genetic variation in CD19 expression correlates with autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.010

10.1016/J.YEXCR.2011.03.010

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference